3-碘-1H-吡唑并[3,4-B]吡啶 | 117007-52-0

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 3-碘-1H-吡唑并[3,4-B]吡啶
• 中文别名: 3-碘-1H-吡唑并[3,4-b]吡啶；1-H-吡唑[3,4B]吡啶-3-碘；3-碘-1H-吡唑
• 英文名称: 3-iodo-1H-pyrazolo[3,4-b]pyridine
• 英文别名: 3-iodo-2H-pyrazolo[3,4-b]pyridine
• CAS: 117007-52-0
• 化学式: C₆H₄IN₃
• 分子量: 245.022
• InChiKey: TYXAGVKIICJXGF-UHFFFAOYSA-N

物化性质

• 熔点：
  177-179°C
• 沸点：
  379.8±22.0 °C(Predicted)
• 密度：
  2.219±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Iodo-1h-pyrazolo[3,4-b]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Iodo-1h-pyrazolo[3,4-b]pyridine
CAS number: 117007-52-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4IN3
Molecular weight: 245

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-碘-1H-吡唑并[3,4-B]吡啶是一种有机中间体，可通过将1H-吡唑并[3,4-b]吡啶进行碘代反应得到。有文献报道，该化合物可用于制备化合物3-(2-{[6-(三氟甲基)吡啶-3-基]氧基}吡啶-3-基)吡唑并[1,5-a]吡啶。

制备

将吡唑并[1,5-a]吡啶(M-5)(300 mg，2.54 mmol)溶解于乙腈(5.0 mL)中，加入NIS(628 mg，2.79 mmol)，室温搅拌1小时。过滤后，在减压下蒸去溶剂。将残留物通过硅胶柱色谱(正己烷:乙酸乙酯)纯化，从而以淡黄色固体的形式得到3-碘-1H-吡唑并[3,4-B]吡啶，收率为556 mg（90%）。

反应信息

• 作为反应物：
  描述：

  3-碘-1H-吡唑并[3,4-B]吡啶 在 1,1'-双(二苯基膦)二茂铁 、 四(三苯基膦)钯 、 potassium carbonate 、 锌 作用下， 以 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲腈
  参考文献：
  名称：

  用于治疗炎症性肠病的新型 hDHODH 抑制剂的发现和优化

  摘要：

  作为嘧啶核苷酸从头合成的关键限速酶，人二氢乳清酸脱氢酶（ h DHODH）被认为是治疗自身免疫性疾病（包括炎症性肠病（IBD））的已知靶标。在此，通过筛选包含 5091 个分子的活性化合物库，将具有 1 H-吡唑并[3,4- b ]吡啶支架的 BAY 41-2272 鉴定为h DHODH 抑制剂。进一步优化得到2-(1-(2-氯-6-氟苄基)-1 H-吡咯并[2,3- b ]吡啶-3-基)-5-环丙基嘧啶-4-胺( w2)，其为被发现是最有前途的类药物化合物，对h DHODH 具有有效的抑制活性（IC 50 = 173.4 nM）。化合物w2表现出可接受的药代动力学特征，并以剂量​​依赖性方式减轻由葡聚糖硫酸钠诱导的急性溃疡性结肠炎的严重程度。值得注意的是，w2对溃疡性结肠炎的治疗效果优于h DHODH抑制剂维多氟地莫和Janus激酶（JAK）抑制剂托法替布。综上所述，w2是一种很有前景的h

  DOI：

  10.1021/acs.jmedchem.3c01365
• 作为产物：
  描述：

  3-氨基-1H-吡唑并[3,4-b]吡啶 在 三氟化硼乙醚 、 亚硝酸异戊酯 、 碘化钠 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 以39%的产率得到3-碘-1H-吡唑并[3,4-B]吡啶
  参考文献：
  名称：

  3-（三氟甲基）-1 H-吡唑并-[3,4- b ]吡啶作为通用构件的用途

  摘要：

  描述了使用定向邻位金属化（DoM）技术从2-氟吡啶开始的一锅法合成3-（三氟甲基）-1 H-吡唑并[3,4- b ]吡啶的方法。该化合物包含可阴离子活化的三氟甲基，是用于微波辅助合成3取代的1 H-吡唑并[3,4- b ]吡啶的通用结构单元。

  DOI：

  10.1016/j.tet.2015.06.050

文献信息

• [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100730A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• NOVEL RENIN INHIBITOR
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20150232459A1

  公开（公告）日：2015-08-20

  The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R 1 is a cycloalkyl group or an alkyl, R 22 is an optionally substituted aryl and the like, R is a lower alkyl group, R 3 , R 4 , R 5 and R 6 are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种公式[I]的含氮饱和杂环化合物，其作为肾素抑制剂有用。 其中R1是环烷基或烷基， R22是可选择取代的芳基等， R是较低的烷基， R3、R4、R5和R6相同或不同，是氢原子、可选择取代的氨基甲酰基、可选择取代的烷基或烷氧羰基， 或其药用可接受盐。
• SOLUBLE GUANYLATE CYCLASE STIMULATORS
  申请人：Berger Raphaelle

  公开号：US20170174693A1

  公开（公告）日：2017-06-22

  The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R 1 , R 2 , R 4 , R a , and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

  该发明提供了Formula (I)的化合物或其药用盐，其中X、Y、Z、R1、R2、R4、Ra以及下标m、p和q如本文所述。这些化合物或其药用盐可以调节人体对环鸟苷酸单磷酸（“cGMP”）的产生，并通常适用于治疗和预防与扰乱的cGMP平衡相关的疾病。该发明还提供了包含Formula (I)的化合物或其药用盐的药物组合物。该发明还涉及使用这些化合物或其药用盐在治疗和预防上述疾病以及为此目的制备药物的方法。
• Selective C–H Iodination of (Hetero)arenes
  作者：Lalita Tanwar、Jonas Börgel、Johannes Lehmann、Tobias Ritter

  DOI：10.1021/acs.orglett.1c01530

  日期：2021.7.2

  Iodoarenes are versatile intermediates and common synthetic targets in organic synthesis. Here, we present a strategy for selective C–H iodination of (hetero)arenes with a broad functional group tolerance. We demonstrate the utility and differentiation to other iodination methods of supposed sulfonyl hypoiodites for a set of carboarenes and heteroarenes.

  碘芳烃是有机合成中的多功能中间体和常见合成目标。在这里，我们提出了一种具有广泛官能团耐受性的（杂）芳烃的选择性 C-H 碘化策略。我们证明了磺酰基次碘酸盐对一组碳芳烃和杂芳烃的实用性和与其他碘化方法的区别。
• [EN] PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE TRIAZINE, ET LEUR UTILISATION COMME INHIBITEURS D'AXL
  申请人：PFIZER

  公开号：WO2016097918A1

  公开（公告）日：2016-06-23

  Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  公式(I)的化合物： (I) 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。